Impact of human IGA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies

Archivum Immunologiae et Therapiae Experimentalis

Volumn 58, Issue 4, 2010, Pages 303-312

  Lohse, Stefan ^a   Peipp, Matthias ^a   Beyer, Thomas ^a   Valerius, Thomas ^a   Dechant, Michael ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

CDC; Complement; IgA

Indexed keywords

CETUXIMAB; COMPLEMENT COMPONENT C1Q; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN A1 ANTIBODY; IMMUNOGLOBULIN A2 ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; MATUZUMAB; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; COMPLEMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS;

ANTIBODY SPECIFICITY; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT FIXATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DRUG SCREENING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; OPSONIZATION; STEREOSPECIFICITY; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL LINE; COMPLEMENT FIXATION TEST; IMMUNOLOGY; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION TESTS; COMPLEMENT SYSTEM PROTEINS; EPITOPES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ISOTYPES; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77956232268     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-010-0081-2     Document Type: Article

References (42)

1. Alinari L, Lapalombella R, Andritsos L et al (2007) Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 26:3644-3653
2. Beyer T, Lohse S, Berger S et al (2009) Serum-free production and purification of chimeric IgA antibodies. J Immunol Methods 346:26-37
3. Boehm MK, Woof JM, Kerr MA et al (1999) The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: A study by X-ray and neutron solution scattering and homology modelling. J Mol Biol 286:1421-1447
4. Burritt MF, Calvanico NJ, Mehta S et al (1977) Activation of the classical complement pathway by Fc fragment of human IgA. J Immunol 118:723-725
5. Chintalacharuvu KR, Morrison SL (1999) Production and characterization of recombinant IgA. Immunotechnology 4:165-174
6. Cooper DK (2003) Clinical xenotransplantion-how close are we? Lancet 362:557-559
7. Corthesy B (2002) Recombinant immunoglobulin A: Powerful tools for fundamental and applied research. Trends Biotechnol 20:65-71
8. Dechant M, Valerius T (2001) IgA antibodies for cancer therapy. Crit Rev Oncol Hematol 39:69-77
9. Dechant M, Vidarsson G, Stockmeyer B et al (2002) Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 100:4574-4580
10. Dechant M, Beyer T, Schneider-Merck T et al (2007) Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 179:2936-2943
11. Dechant M, Weisner W, Berger S et al (2008) Complementdependent tumor cell lysis triggered by combinations of EGFR antibodies. Cancer Res 68:4998-5003
12. Di Gaetano N, Cittera E, Nota R et al (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581-1587
13. Fearon DT (1998) The complement system and adaptive immunity. Semin Immunol 10:355-361
14. Furtado PB, Whitty PW, Robertson A et al (2004) Solution structure determination of monomeric human IgA2 by X-ray and neutron scattering, analytical ultracentrifugation and constrainedmodelling: A comparison with monomeric human IgA1. J Mol Biol 338:921-941
15. Gorter A, Meri S (1999) Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 20:576-582
16. Hiemstra PS, Gorter A, Stuurman ME et al (1987) Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol 17:321-326
17. Hiemstra PS, Biewenga J, Gorter A et al (1988) Activation of complement by human serum IgA, secretory IgA and IgA1 fragments. Mol Immunol 25:527-533
18. Huls G, Heijnen IA, Cuomo E et al (1999) Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res 59:5778-5784
19. Jarvis GA, Griffiss JM (1991) Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule. J Immunol 147:1962-1967
20. Kerr MA (1990) The structure and function of human IgA. Biochem J 271:285-296
21. Krebber A, Bornhauser S, Burmester J et al (1997) Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 201:35-55
22. Lazar GA, Dang W, Karki S et al (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103:4005-4010
23. Logtenberg T (2007) Antibody cocktails: Next-generation biopharmaceuticals with improved potency. Trends Biotechnol 25:390-394
24. Maloney DG, Smith B, Rose A (2002) Rituximab: Mechanism of action and resistance. Semin Oncol 29(suppl 1):2-9
25. Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20(18 suppl):1S-13S
26. Monteiro RC, Van De Winkel JG (2003) IgA Fc receptors. Annu Rev Immunol 21:177-204
27. Mostov KE (1994) Transepithelial transport of immunoglobulins. Annu Rev Immunol 12:63-84
28. Nikolova EB, Tomana M, Russell MW (1994) The role of the carbohydrate chains in complement (C3) fixation by solid-phasebound human IgA. Immunology 82:321-327
29. Oortwijn BD, Eijgenraam JW, Rastaldi MP et al (2008) The role of secretory IgA and complement in IgA nephropathy. Semin Nephrol 28:58-65
30. Otten MA, Rudolph E, Dechant M et al (2005) Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol 174:5472-5480
31. Pedersen MW, Steinaa L, Jensen A et al (2008) Recombinant antiepidermal growth factor receptor antibody compositions. Patent WO 2008/104183
32. Peipp M, Kupers H, Saul D et al (2002) A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 62:2848-2855
33. Perkins SJ, Bonner A (2008) Structure determinations of human and chimaeric antibodies by solution scattering and constrained molecular modelling. Biochem Soc Trans 36:37-42
34. Reichert JM, Valge-Archer VE (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6:349-356
35. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ et al (2001) Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 167:2861-2868
36. Russell MW, Reinholdt J, Kilian M (1989) Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: Inhibition of IgG-mediated complement activation. Eur J Immunol 19:2243-2249
37. Taylor RP (2004) CD20 Trek: The next generation. Blood 104:1592
38. van der Steen L, Tuk CW, Bakema JE et al (2009) Immunoglobulin A: FcalphaRI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology 137:2018-2029
39. van Egmond M, Damen CA, van Spriel AB et al (2001) IgA and the IgA Fc receptor. Trends Immunol 22:205-211
40. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058-1066
41. Wines BD, Hogarth PM (2006) IgA receptors in health and disease. Tissue Antigens 68:103-114
42. Woof JM, Kerr MA (2006) The function of immunoglobulin A in immunity. J Pathol 208:270-282